“…In short, there are several potential explanations for these differing results among these studies: first, the relatively small sample size may not precisely represent the larger patients; secondly, the baseline characteristics such as disease duration, age, race and BMI can be inconsistent, which may affect the expression level of leptin; thirdly, patients with other co-existing autoimmune diseases cannot be excluded from studies, which could be potential confounding factors; and fourthly, different measurement methods of leptin levels, such as radioimmunoassay [20,37,40,100] and enzyme-linked immunosorbent assay (ELISA), may also cause deviation [8,23,30]. In addition, discrepancies in leptin levels in RA patients could be due to different treatments that intervene with the endocrine system, which usually complicates human experimental researches.…”